H. Wexler

发表

Anaerobic Infections: A Clinical Overview

H. Wexler, 2015 .

Complete hybrid genome assembly of clinical multidrug-resistant Bacteroides fragilis isolates enables comprehensive identification of antimicrobial-resistance genes and plasmids

H. Hasman, U. S. Justesen, H. Wexler, 2019, Microbial genomics.

Complete genome assembly of clinical multidrug resistant Bacteroides fragilis isolates enables comprehensive identification of antimicrobial resistance genes and plasmids

H. Hasman, U. S. Justesen, H. Wexler, 2019, bioRxiv.

The Genus Bacteroides

H. Wexler, 2014 .

Identification of genes required for the survival of B. fragilis using massive parallel sequencing of a saturated transposon mutant library

Fasahath Husain, H. Wexler, Y. Veeranagouda, 2014, BMC Genomics.

Transposon mutagenesis of the anaerobic commensal, Bacteroides fragilis, using the EZ::TN5 transposome.

H. Wexler, Y. Veeranagouda, Fasahath Husain, 2012, FEMS microbiology letters.

Impact of Anatomic Site on Growth, Efflux-Pump Expression, Cell Structure, and Stress Responsiveness of Bacteroides fragilis

H. Wexler, L. Pumbwe, C. Skilbeck, 2007, Current Microbiology.

Bacteroides: the Good, the Bad, and the Nitty-Gritty

Hannah M. Wexler, H. Wexler, 2007, Clinical Microbiology Reviews.

Clinical significance of overexpression of multiple RND-family efflux pumps in Bacteroides fragilis isolates.

H. Wexler, L. Pumbwe, Abraham Chang, 2006, The Journal of antimicrobial chemotherapy.

Bacteriologic findings associated with chronic bacterial maxillary sinusitis in adults.

B. Wynne, E. Berkowitz, S. Finegold, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Current perspectives on anaerobic infections: diagnostic approaches.

S. Finegold, H. Wexler, H. Jousimies-Somer, 1993, Infectious disease clinics of North America.

Inactivation of anaerobic bacteria by various photosensitized porphyrins or by hemin

Y. Nitzan, S. Finegold, H. Wexler, 1994, Current Microbiology.

The Application of Transposon Insertion Sequencing in Identifying Essential Genes in B. fragilis.

H. Wexler, Y. Veeranagouda, 2021, Methods in molecular biology.

Sutterella Wexler, Reeves, Summanen, Molitoris, McTeague, Duncan, Wilson and Finegold 1996a, 257VP

H. Wexler, 2005 .

Sources and antimicrobial susceptibilities of Campylobacter gracilis and Sutterella wadsworthensis.

S. Finegold, H. Wexler, E. Molitoris, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Short-Term Benefit From Oral Vancomycin Treatment of Regressive-Onset Autism

C P Buchanan, R H Sandler, R. Sandler, 2000, Journal of child neurology.

Gastrointestinal microflora studies in late-onset autism.

Haroun Shah, Richard Sandler, Erik Read, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Rapid identification of the species of the Bacteroides fragilis group by multiplex PCR assays using group- and species-specific primers.

S. Finegold, H. Wexler, M. McTeague, 2003, FEMS microbiology letters.

Isolation and characterization of porins from Desulfovibrio piger and Bilophila wadsworthia: structure and gene sequencing

Y. Nitzan, I. Pechatnikov, A. Shainskaya, 2008, Archives of Microbiology.

Activities of ABT-773 against Microaerophilic and Fastidious Organisms

S. Finegold, H. Wexler, D. Molitoris, 2002, Antimicrobial Agents and Chemotherapy.

Isolation and characterization of the Omp-PA porin from Porphyromonas asaccharolytica, determination of the omp-PA gene sequence and prediction of Omp-PA protein structure.

Y. Nitzan, I. Pechatnikov, H. Wexler, 2007, Anaerobe.

CRISPR-Cas Systems in Bacteroides fragilis, an Important Pathobiont in the Human Gut Microbiome

M. Tajkarimi, H. Wexler, 2017, Front. Microbiol..

Induction of multiple antibiotic resistance in Bacteroides fragilis by benzene and benzene-derived active compounds of commonly used analgesics, antiseptics and cleaning agents.

H. Wexler, L. Pumbwe, C. Skilbeck, 2007, The Journal of antimicrobial chemotherapy.

Bowel flora changes in humans receiving cefixime (CL 284,635) or cefaclor

L. Ingram-drake, S. Finegold, H. Wexler, 1987, Antimicrobial Agents and Chemotherapy.

Adherence and invasion of Bacteroidales isolated from the human intestinal tract.

W. Elias, R. Piazza, H. Wexler, 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Sixteen Homologs of the Mex-Type Multidrug Resistance Efflux Pump in Bacteroides fragilis

F. Yoshimura, H. Wexler, K. Hirai, 2005, Antimicrobial Agents and Chemotherapy.

Morphological response of Bilophila wadsworthia to imipenem: correlation with properties of penicillin-binding proteins

S. Becker, S. Finegold, H. Wexler, 1993, Antimicrobial Agents and Chemotherapy.

RAPID MULTIPLEX PCR ASSAY FOR SIMULTANEOUS DETECTION OF MAJOR ANTIBIOTIC RESISTANCE DETERMINANTS IN CLINICAL ISOLATES OF BACTEROIDES FRAGILIS

H. Wexler, L. Pumbwe, Matthew Curzon, 2008 .

Antianaerobic Antimicrobials: Spectrum and Susceptibility Testing

I. Brook, E. Goldstein, H. Wexler, 2013, Clinical Microbiology Reviews.

Antimicrobial resistance and prevalence of resistance genes in intestinal Bacteroidales strains

H. Wexler, M. J. Ávila-Campos, V. Nakano, 2011, Clinics.

Bilophila wadsworthia, gen. nov. and sp. nov., a unique gram-negative anaerobic rod recovered from appendicitis specimens and human faeces.

E. Baron, S. Finegold, M. Roberts, 1989, Journal of general microbiology.

Role of Topoisomerase Mutations and Efflux in Fluoroquinolone Resistance of Bacteroides fragilis Clinical Isolates and Laboratory Mutants

J. Rotschafer, V. Ricci, L. Piddock, 2004, Antimicrobial Agents and Chemotherapy.

Microbial flora in the bypassed jejunum of patients with biliopancreatic bypass for obesity.

E. Drenick, S. Finegold, H. Wexler, 1987, The American journal of clinical nutrition.

Isolation and characterization of heat-modifiable proteins from the outer membrane of Porphyromonas asaccharolytica and Acinetobacter baumannii.

Y. Nitzan, I. Pechatnikov, H. Wexler, 1999, Anaerobe.

The isolation and characterisation of a major outer-membrane protein from Bacteroides distasonis.

H. Wexler, C. Getty, G. Fisher, 1992, Journal of medical microbiology.

Cytokine release and expression induced by OmpA proteins from the Gram-negative anaerobes, Porphyromonas asaccharolytica and Bacteroides fragilis.

Y. Nitzan, I. Pechatnikov, H. Wexler, 2008, FEMS immunology and medical microbiology.

Susceptibility testing of anaerobic bacteria: myth, magic, or method?

H. Wexler, H. M. Wexler, 1991, Clinical Microbiology Reviews.

Present Status of Therapy for Anaerobic Infections

S. Finegold, H. Wexler, 1996 .

Susceptibility Testing ofAnaerobic Bacteria: Myth,Magic, orMethod?

H. Wexler, 1991 .

Therapeutic implications of bacteriologic findings in mixed aerobic-anaerobic infections

S. Finegold, H. Wexler, Medical ' andResearch, 1988, Antimicrobial Agents and Chemotherapy.

Antimicrobial susceptibility testing of Bilophila wadsworthia by using triphenyltetrazolium chloride to facilitate endpoint determination

S. Finegold, H. Wexler, P. Summanen, 1992, Antimicrobial Agents and Chemotherapy.

Impact of imipenem/cilastatin therapy on normal fecal flora.

S. Finegold, H. Wexler, 1985, The American journal of medicine.

In Vitro Activities of Doripenem and Comparator Agents against 364 Anaerobic Clinical Isolates

H. Wexler, D. Glass, Adrian E Engel, 2005, Antimicrobial Agents and Chemotherapy.

In Vitro Activities of Faropenem against 579 Strains of Anaerobic Bacteria

E. Read, S. Finegold, H. Wexler, 2002, Antimicrobial Agents and Chemotherapy.

Susceptibility testing of anaerobic bacteria--the state of the art.

H. Wexler, 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

35 – Susceptibility Testing Procedures

H. Wexler, 1989 .

InVitro Activity ofCefoperazone plusSulbactam Compared with ThatofOther Antimicrobial Agents against Anaerobic Bacteria

H. Wexler, 1988 .

In vitro activity of cefotetan compared with that of other antimicrobial agents against anaerobic bacteria

S. Finegold, H. Wexler, 1988, Antimicrobial Agents and Chemotherapy.

In vitro activity of telithromycin (HMR 3647) against 502 strains of anaerobic bacteria.

S. Finegold, H. Wexler, D. Molitoris, 2001, The Journal of antimicrobial chemotherapy.

Effects of differences in media and methods on MIC values for anaerobes.

S. Finegold, H. Wexler, 1990, Hospital practice.

In vitro activity of cefoperazone plus sulbactam compared with that of other antimicrobial agents against anaerobic bacteria

S. Finegold, H. Wexler, 1988, Antimicrobial Agents and Chemotherapy.

Son of anaerobic susceptibility testing— Revisited

E. Baron, D. Citron, H. Wexler, 1990 .

Comparison of spiral gradient endpoint and agar dilution methods for susceptibility testing of anaerobic bacteria: a multilaboratory collaborative evaluation

P. Murray, P. Edelstein, J. Washington, 1996, Journal of clinical microbiology.

Effect of inoculum size and medium on activity of seven antimicrobial agents against Bacteroides fragilis strains.

S. Finegold, H. Wexler, D. Reeves, 1989, Clinical therapeutics.

Cell-wall-defective variants of Fusobacterium

S. Becker, S. Finegold, H. Wexler, 1989, Antimicrobial Agents and Chemotherapy.

Comparison of in vitro antibiograms of Bacteroides fragilis group isolates: differences in resistance rates in two institutions because of differences in susceptibility testing methodology

K. Aldridge, C. Sanders, S. Finegold, 1990, Antimicrobial Agents and Chemotherapy.

Antibiotic susceptibility testing of anaerobic organisms using the agar dilution method: comparison of three techniques.

S. Finegold, H. Wexler, D. Reeves, 1988, Clinical therapeutics.

Antimicrobial resistance in Bacteroides.

S. Finegold, H. Wexler, 1987, The Journal of antimicrobial chemotherapy.

Effect of beta-lactamase inhibitors on the activities of various beta-lactam agents against anaerobic bacteria

S. Finegold, H. Wexler, E. Molitoris, 1991, Antimicrobial Agents and Chemotherapy.

In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria

S. Finegold, W. T. Carter, H. Wexler, 1985, Antimicrobial Agents and Chemotherapy.

In vitro activity of cefbuperazone against anaerobic bacteria

S. Finegold, W. T. Carter, H. Wexler, 1985, Antimicrobial Agents and Chemotherapy.

Multilaboratory comparison of anaerobe susceptibility results using 3 different agar media.

D. E. Roe, J. Rosenblatt, E. Goldstein, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Multilaboratory comparison of growth characteristics for anaerobes, using 5 different agar media.

J. Rosenblatt, E. Goldstein, S. Jenkins, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparison of spiral gradient and conventional agar dilution for susceptibility testing of anaerobic bacteria

S. Finegold, H. Wexler, E. Molitoris, 1991, Antimicrobial Agents and Chemotherapy.

Comparative activity of SCH 34343 against anaerobic bacteria.

S. Finegold, H. Wexler, V. Sutter, 1986, Diagnostic microbiology and infectious disease.

Current susceptibility patterns of anaerobic bacteria.

S. Finegold, H. Wexler, 1998, Yonsei medical journal.

Sutterella wadsworthensis gen. nov., sp. nov., bile-resistant microaerophilic Campylobacter gracilis-like clinical isolates.

K. Wilson, S. Finegold, K H Wilson, 1996, International Journal of Systematic Bacteriology.

Preliminary study using species-specific oligonucleotide probe for rRNA of Bilophila wadsworthia

K. Wilson, S. Finegold, F. Sapico, 1994, Journal of clinical microbiology.

Mitogenic and adjuvant properties of the LPS-like component of Listeria monocytogenes

N. Bhardwaj, J. Oppenheim, H. Wexler, 1981 .

Isolation, characterization, and biological properties of an endotoxin-like material from the gram-positive organism Listeria monocytogenes

J. Oppenheim, H. Wexler, 1979, Infection and immunity.

Bacteroides fragilis BmeABC efflux systems additively confer intrinsic antimicrobial resistance.

F. Yoshimura, H. Wexler, L. Pumbwe, 2006, The Journal of antimicrobial chemotherapy.

In-vitro susceptibilities of Bacteroides gracilis, Fusobacterium mortiferum and F. varium to 17 antimicrobial agents.

E. Baron, R. Courcol, S. Finegold, 1990, The Journal of antimicrobial chemotherapy.

In vitro activities of two new glycylcyclines, N,N-dimethylglycylamido derivatives of minocycline and 6-demethyl-6-deoxytetracycline, against 339 strains of anaerobic bacteria

S. Finegold, H. Wexler, E. Molitoris, 1994, Antimicrobial Agents and Chemotherapy.

InVitro Activities ofTwoNewGlycylcyclines, N,N-Dimethylglycylamido Derivatives ofMinocycline and6-Demethyl-6-Deoxytetracycline, against 339Strains ofAnaerobic Bacteria

S. Finegold, H. Wexler, Medical ' andResearch, 1994 .

In vitro Activity of Moxifloxacin Against 179 Strains of Anaerobic Bacteria Found in Pulmonary Infections

S. Finegold, H. Wexler, D. Molitoris, 2000 .

In vitro activity of DU-6859a against anaerobic bacteria

S. Finegold, H. Wexler, D. Reeves, 1994, Antimicrobial Agents and Chemotherapy.

In vitro activity of ertapenem: review of recent studies.

H. Wexler, 2004, The Journal of antimicrobial chemotherapy.

Alterations to the penicillin-binding proteins in the Bacteroides fragilis group: a mechanism for non-beta-lactamase mediated cefoxitin resistance.

H. Wexler, S. Halebian, 1990, The Journal of antimicrobial chemotherapy.

In vitro susceptibility of anaerobes to quinolones in the United States.

D. Hecht, H. Wexler, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Bacteroides fragilis cell envelope: quarterback, linebacker, coach-or all three?

H. Wexler, L. Pumbwe, C. Skilbeck, 2006, Anaerobe.

In Vitro Antibacterial Properties of Pexiganan, an Analog of Magainin

K. Holroyd, H. Wexler, C. Thornsberry, 1999, Antimicrobial Agents and Chemotherapy.

Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin.

D. Citron, A. Barry, P. Fuchs, 1993, The Journal of antimicrobial chemotherapy.

In vitro activities of three of the newer quinolones against anaerobic bacteria

S. Finegold, H. Wexler, E. Molitoris, 1992, Antimicrobial Agents and Chemotherapy.

In-vitro activity of temafloxacin against anaerobic bacteria: a comparative study.

S. Finegold, H. Wexler, D. Reeves, 1991, The Journal of antimicrobial chemotherapy.

In Vitro Activity of Levofloxacin against a Selected Group of Anaerobic Bacteria Isolated from Skin and Soft Tissue Infections

S. Finegold, H. Wexler, D. Molitoris, 1998, Antimicrobial Agents and Chemotherapy.

In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria

S. Finegold, H. Wexler, D. Molitoris, 1996, Antimicrobial agents and chemotherapy.

In vitro activity of Bay Y3118 against anaerobic bacteria

S. Finegold, H. Wexler, E. Molitoris, 1993, Antimicrobial Agents and Chemotherapy.

Adherence of Bilophila wadsworthia to cultured human embryonic intestinal cells.

S. Finegold, H. Wexler, M. Garcia, 1998, Anaerobe.

Two Multidrug-Resistant Clinical Isolates of Bacteroides fragilis Carry a Novel Metronidazole Resistance nim Gene (nimJ)

V. Abratt, H. Wexler, Y. Veeranagouda, 2013, Antimicrobial Agents and Chemotherapy.

BmeRABC5 is a multidrug efflux system that can confer metronidazole resistance in Bacteroides fragilis.

H. Wexler, L. Pumbwe, Abraham Chang, 2007, Microbial drug resistance.

Pump it up: occurrence and regulation of multi-drug efflux pumps in Bacteroides fragilis.

H. Wexler, 2012, Anaerobe.

Bile salts enhance bacterial co-aggregation, bacterial-intestinal epithelial cell adhesion, biofilm formation and antimicrobial resistance of Bacteroides fragilis.

H. Wexler, R. Piazza, M. J. Ávila-Campos, 2007, Microbial pathogenesis.

Presence of Quorum-sensing Systems Associated with Multidrug Resistance and Biofilm Formation in Bacteroides fragilis

H. Wexler, L. Pumbwe, C. Skilbeck, 2008, Microbial Ecology.

Genetic analysis of mechanisms of multidrug resistance in a clinical isolate of Bacteroides fragilis.

D. Wareham, J. Brazier, H. Wexler, 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Efflux Pump Overexpression in Multiple-Antibiotic-Resistant Mutants of Bacteroides fragilis

H. Wexler, L. Pumbwe, D. Glass, 2006, Antimicrobial Agents and Chemotherapy.

Novel large-scale chromosomal transfer in Bacteroides fragilis contributes to its pan-genome and rapid environmental adaptation

K. Tang, H. Wexler, S. Patrick, 2017, Microbial genomics.

Characteristics of Bacteroides fragilis lacking the major outer membrane protein, OmpA.

H. Wexler, L. Pumbwe, Elizabeth L Tenorio, 2009, Microbiology.

Bacteroides Fragilis OmpA: Utility as a Live Vaccine Vector for Biodefense Agents

H. Wexler, 2006 .

Diagnosis of antibiotic-associated disease caused by Clostridium difficile

H. Wexler, 1989 .

Chapter 16 – Other Potential Diagnostic Techniques

Hannah M. Wexler, H. Wexler, 1988 .

Polyacrylamide gel electrophoresis patterns produced by Clostridium difficile.

M. Mulligan, S. Finegold, H. Wexler, 1984, Reviews of infectious diseases.

Activity of ABT-773 Against Bowel Flora Organisms

S. Finegold, H. Wexler, D. Molitoris, 2002 .

Outer-membrane pore-forming proteins in gram-negative anaerobic bacteria.

H. Wexler, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Transposon Mutagenesis of Bacteroides fragilis.

H. Wexler, Y. Veeranagouda, Fasahath Husain, 2019, Methods in molecular biology.

Deficiency of the ferrous iron transporter FeoAB is linked with metronidazole resistance in Bacteroides fragilis.

E. R. Rocha, C. Smith, H. Wexler, 2014, The Journal of antimicrobial chemotherapy.

Transposon mutagenesis of Bacteroides fragilis using a mariner transposon vector.

H. Wexler, Y. Veeranagouda, Fasahath Husain, 2013, Anaerobe.

Rapid identi¢cation of the species of the Bacteroides fragilis group by multiplex PCR assays using group- and species-speci¢c primers

S. Finegold, H. Wexler, M. McTeague, 2003 .

Susceptibility testing of anaerobes: old problems, new options?

H. Wexler, D. Molitoris, E. Molitoris, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Identification of an OmpA Protein from Bacteroides fragilis: omp A Gene Sequence, OmpA Amino Acid Sequence and Predictions of Protein Structure

E. Read, H. Wexler, Thomas J. Tomzynski, 2002 .

Characterization of omp200, a porin gene complex from Bacteroides fragilis: omp121 and omp71, gene sequence, deduced amino acid sequences and predictions of porin structure.

E. Read, H. Wexler, Thomas J. Tomzynski, 2002, Gene.

Biochemical and polyacrylamide gel electrophoretic analyses of vaginosis-associated anaerobic curved rods.

E. Baron, S. Finegold, H. Wexler, 1984, Scandinavian journal of urology and nephrology. Supplementum.

Gangrenous and/or perforated appendix: clinical outcome and in vitro susceptibility testing.

E. Baron, R. Bennion, S. Finegold, 1990, Hospital practice.

In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.

S. Finegold, H. Wexler, D. Reeves, 1994, The Journal of antimicrobial chemotherapy.

Pore-forming molecules in gram-negative anaerobic bacteria.

H. Wexler, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Statistical analysis of the effects of trial, reader, and replicates on MIC determination for cefoxitin

P. Lavin, S. Finegold, H. Wexler, 1990, Antimicrobial Agents and Chemotherapy.

The Ellis Island Effect

K. Tang, H. Wexler, Y. Veeranagouda, 2014, Mobile genetic elements.

Six-year retrospective survey of the resistance of Bacteroides fragilis group species to clindamycin and cefoxitin.

S. Finegold, W. T. Carter, H. Wexler, 1986, Diagnostic microbiology and infectious disease.

Comparative in vitro activities of cefpiramide and apalcillin against anaerobic bacteria

S. Finegold, W. T. Carter, H. Wexler, 1984, Antimicrobial Agents and Chemotherapy.

Changes in the antibiotic susceptibility of anaerobic bacteria from 2007-2009 to 2010-2012 based on the CLSI methodology.

Maria Karlsson, Audrey N Schuetz, L. Koeth, 2016, Anaerobe.

In Vitro Activities of MK-826 (L-749,345) against 363 Strains of Anaerobic Bacteria

S. Finegold, H. Wexler, D. Molitoris, 2000, Antimicrobial Agents and Chemotherapy.

Present studies of therapy for anaerobic infections.

S. Finegold, H. Wexler, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Multilaboratory evaluation of an agar diffusion disk susceptibility test for rapidly growing anaerobic bacteria.

R. Jones, K. Aldridge, A. Bourgault, 1990, Reviews of infectious diseases.

The isolation and characterization of a porin protein fromBacteroides fragilis

H. Wexler, C. Getty, 1996 .

Identification of genes required for the survival of B. fragilis using massive parallel sequencing of a saturated transposon mutant library

H. Wexler, Y. Veeranagouda, Fasahath Husain, 2014, BMC Genomics.

In vitro activity of HMR 3004 (RU 64004) against 502 strains of anaerobic bacteria

S. Finegold, H. Wexler, D. Molitoris, 1999 .

Molecular Interactions in T‐Cell‐Mediated Cytotoxicity

R. Effros, B. Bonavida, H. Wexler, 1983, Immunological reviews.

In vitro activity of imipenem against anaerobic bacteria.

S. Finegold, H. Wexler, 1985, Reviews of infectious diseases.